BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

Further evidence that US Department of Health and Human Services (HHS) secretary Robert F Kennedy Junior (RFK Jr) is willing ...

Analysts have recently evaluated BioNTech and provided 12-month price targets. The average target is $134.42, accompanied by ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

Does BioNTech SE Sponsored ADR (BNTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Global vaccine stocks traded lower on Wednesday after the U.S. Department of Health and Human Services announced it would ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...